2013-10-14 16:06:53 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Conpharm AB (CONP B) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Conpharm AB (CONP B). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Conpharm AB investor.
Report Summary: Conpharm AB is a low quality company with a negative outlook. Conpharm AB has weak business growth and is run by mediocre management. The trend in Conpharm AB fair value exchange rate against its closest rated-competitor, Swedish Orphan Biovitrum AB, has been depreciating over the past 2 weeks. When compared to its closest competitor, Conpharm AB shows similar overvaluation and is equally likely to underperform the market.
The report breaks down the Total StockMark into its three components - business, management
and price, performing an in-depth analysis of Conpharm AB for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.